Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance

The epidermal growth factor receptor inhibitor cetuximab is the only oncogene-targeted agent that has been FDA approved for the treatment of head and neck squamous cell carcinoma (HNSCC). Currently, there are no biomarkers used in the clinic to predict which HNSCC tumors will respond to cetuximab, a...

Descripción completa

Detalles Bibliográficos
Autores principales: O’Keefe, Rachel A., Bhola, Neil E., Lee, David S., Johnson, Daniel E., Grandis, Jennifer R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948745/
https://www.ncbi.nlm.nih.gov/pubmed/31914141
http://dx.doi.org/10.1371/journal.pone.0227261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6948745/
https://www.ncbi.nlm.nih.gov/pubmed/31914141
http://dx.doi.org/10.1371/journal.pone.0227261

Ejemplares similares